ArticleNature2024
SMYD5 methylation of rpL40 links ribosomal output to gastric cancer.
Abstract read
In one paragraph
Article in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Ribosome remodeling drives translation adaptation during viral infection and cellular stress.Molecular cell · 2026Article
- Epigenetic Functions of SMYD5 and Its Role in Development, Cancer and Other Cellular Processes.International journal of molecular sciences · 2026Review
- Role of histone modifications in gastric cancer (Review).International journal of oncology · 2026Review
- EEF1AKMT4-eEF1A2 synergistically facilitates the progression of GBC by promoting ribosomal protein output.Genes & diseases · 2026Article
- Multi omics and mechanistic investigation reveals CBFB as a prognostic biomarker in gastric cancer.Discover oncology · 2026Article
- Backbone Thioamidation of a Ribosomal Subunit Protein in Pseudomonadota.Biochemistry · 2026Article
- Ribosome heterogeneity and specialization in musculoskeletal physiology and pathology.JBMR plus · 2026Article
- Construction and application of a genetically engineered mouse model of gastric adenocarcinoma.Journal of the Chinese Medical Association : JCMA · 2026Article
- Many faces of mammalian NSD methyltransferases.Cellular & molecular biology letters · 2026Review
- First analysis of Spirometra mansoni excretory-secretory proteins by the 4D-DIA method.Parasite (Paris, France) · 2026Article
- Article
- Chromatin stability safeguards mitochondrial homeostasis and prevents mTORC1 hyperactivation.bioRxiv : the preprint server for biology · 2025Article
- Review
- METTL10-Mediated PIAS3 Methylation Links Purine Metabolism to Gastric Cancer Progression.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Ribosome remodeling drives translation adaptation during viral infection and cellular stress.bioRxiv : the preprint server for biology · 2025Article
- Proteomic Analysis Uncovers Enhanced Inflammatory Phenotype and Distinct Metabolic Changes in IDH1 Mutant Glioma Cells.International journal of molecular sciences · 2025Article
- SETD2 suppresses tumorigenesis in a KRASeLife · 2025Article
- PFKM Promotes the Progression of Gastric Cancer by Up-regulating CNTN1 Expression Through H3K18la Modification.Applied biochemistry and biotechnology · 2025Article
- SMYD5-BRD4 Interaction Drives Hepatocellular Carcinoma Progression: A Combined in Silico and Experimental Analysis.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Stemness signatures reflect prognostic disturbances in gastric cancer.World journal of gastrointestinal oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Juhyung Park *Department of Biology, Stanford University, Stanford, CA, USA.ORCID 0009-0008-6916-2784
Jibo Wu *Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Krzysztof J SzkopDepartment of Oncology-Pathology, Science for Life Laboratories, Karolinska Institute, Stockholm, Sweden.
Jinho JeongDepartment of Biology, Stanford University, Stanford, CA, USA.ORCID 0000-0002-1224-7196
Predrag JovanovicLady Davis Institute and Gerald Bronfman Department of Oncology, McGill University, Montreal, Quebec, Canada.ORCID 0000-0002-0090-0047
Dylan HusmannDepartment of Biology, Stanford University, Stanford, CA, USA.ORCID 0000-0003-1995-7892
Natasha M FloresDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Joel W FrancisDepartment of Biology, Stanford University, Stanford, CA, USA.
Ying-Jiun C ChenDepartment of Biology, Stanford University, Stanford, CA, USA.ORCID 0000-0002-6290-0771
Ana Morales BenitezDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-1021-5262
Emily ZahnDepartment of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St Louis, MO, USA.
Shumei SongDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-8128-6287
Jaffer A AjaniDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-9946-0629
Linghua WangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-9380-0266
Kamini SinghDepartment of Molecular Pharmacology, Albert Einstein College of Medicine, Montefiore Einstein Cancer Center, Bronx, NY, USA.
Ola LarssonDepartment of Oncology-Pathology, Science for Life Laboratories, Karolinska Institute, Stockholm, Sweden.ORCID 0000-0003-1412-1308
Benjamin A GarciaDepartment of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St Louis, MO, USA.ORCID 0000-0003-3596-4750
Ivan TopisirovicLady Davis Institute and Gerald Bronfman Department of Oncology, McGill University, Montreal, Quebec, Canada.ORCID 0000-0002-5510-9762
Or GozaniDepartment of Biology, Stanford University, Stanford, CA, USA. ogozani@stanford.edu.ORCID 0000-0002-1365-4463
Pawel K MazurDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. pkmazur@mdanderson.org.ORCID 0000-0002-5820-8344
Funding
Supplement to Enhance Wellness and Resiliency in the Graduate EnvironmentT32GM007276 · NIGMS · STANFORD UNIVERSITY · PI MORRISON, ASHBY J. · 1985 to 2023
$32.9MViral modulation of epitranscriptomic mechanismsR01AI118891 · NIAID · WASHINGTON UNIVERSITY · PI GARCIA, BENJAMIN A, WEITZMAN, MATTHEW D. · 2015 to 2025
$5.4MFunction of Protein Methylation in Chromatin and Signaling RegulationR35GM139569 · NIGMS · STANFORD UNIVERSITY · PI Or P. Gozani · 2021 to 2026
$4.0MTumor cell lineage diversity and composition in gastric cancer progression and therapy resistanceR01CA266280 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Pawel K. Mazur, Linghua Wang · 2022 to 2026
$3.2MQuantitative mass spectrometry for comprehending epigenetic mechanisms in a new underlying neurological developmental disorderR01HD106051 · NICHD · WASHINGTON UNIVERSITY · PI Benjamin A Garcia · 2022 to 2026
$2.6MTherapeutic Targeting of NSD2 in Lung AdenocarcinomaR01CA272844 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Or P. Gozani, Pawel K. Mazur · 2023 to 2026
$2.6MMechanisms of action and therapeutic targeting of the CARM1-NFIB axis in small cell lung cancerR01CA272843 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MARK T. BEDFORD, Pawel K. Mazur · 2023 to 2026
$2.6MRole of NSD3 in regulation of cancer pathogenesisR01CA278940 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Or P. Gozani, Pawel K. Mazur · 2023 to 2026
$2.6MRole of the METTL13 Lysine Methyltransferase in Signaling and CancerR01CA236118 · NCI · STANFORD UNIVERSITY · PI GOZANI, OR P., MAZUR, PAWEL K. · 2019 to 2023
$2.4MMolecular dissecting and targeting YAP1 mediated cancer stemness and immune suppression in advanced gastric adenocarcinomaR01CA269685 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SONG, SHUMEI · 2022 to 2025
$2.2MRole of SETD5 in Chromatin Regulation and TumorigenesisR01CA236949 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MAZUR, PAWEL K. · 2019 to 2023
$1.9MRole of the candidate protein methyltransferase METTL18 in cancer biologyF31CA261128 · NCI · STANFORD UNIVERSITY · PI FRANCIS, JOEL · 2022 to 2023
$70kNCI NIH HHS F31 CA261128NCI NIH HHS R01 CA236118NCI NIH HHS R01 CA236949NCI NIH HHS R01 CA266280NCI NIH HHS R01 CA269685NCI NIH HHS R01 CA272843NCI NIH HHS R01 CA272844NCI NIH HHS R01 CA278940NIAID NIH HHS R01 AI118891NICHD NIH HHS R01 HD106051NIGMS NIH HHS R35 GM139569NIGMS NIH HHS T32 GM007276
Abstract
Dysregulated transcription due to disruption in histone lysine methylation dynamics is an established contributor to tumorigenesis
Indexed as
MethyltransferasesRibosomal ProteinsRibosomesStomach NeoplasmsAdenocarcinomaAnimalsCell Line, TumorDisease Models, AnimalDisease ProgressionEpigenesis, GeneticFemaleGene Expression Regulation, NeoplasticHistone-Lysine N-MethyltransferaseHumansLysineMethylationHistone-Lysine N-MethyltransferaseLysineMethyltransferasesMTOR protein, humanPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsRibosomal ProteinsRNA, MessengerSMYD5 protein, humanTOR Serine-Threonine KinasesUBA52 protein, human
Identifiers
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.